In this issue:
Model for end-stage liver disease to predict short-term mortality in severe flares of chronic hepatitis B
HBV particles activate toll-like receptor 2 signalling initially upon infection of primary human hepatocytes
HCV NAT-positive solid organ allografts transplanted into HCV-negative recipients
Pregenomic HBV RNA and HBcrAg predict outcomes in HBeAg-negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy
Efficacy of NS5A inhibitors against unusual HCV subtypes
Diverse effects of hepatic steatosis on fibrosis progression and functional cure in chronic hepatitis B
Hepatic impairment in patients with COVID-19
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis
Chronic hepatitis D and HCC
Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis
Please login below to download this issue (PDF)